Long-term follow-up for adults taking Sogroya for growth hormone deficiency
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This study follows adults with growth hormone deficiency who start (or have started) Sogroya to learn about its long-term safety. It does not change your treatment—it mainly checks for side effects and health outcomes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older when you agree to join
- Have been diagnosed with adult growth hormone deficiency (AGHD) by your usual doctor
- Decide to start Sogroya on your own and with your treating doctor—before agreeing to this study
- Be able and willing to understand and cooperate with the study (no language barriers or inability to consent)
- Not have had consent for this study before (only one time per person)
- No known allergy to Sogroya ingredients and no ongoing/recent active cancer being treated
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new growth hormone treatment called GenSci134 in healthy adults and adults with growth hormone deficiency (AGHD). The goal is to see if it is safe and effective for people who need growth hormone replacement.
This study tests a new injectable growth hormone treatment for adults whose bodies don't produce enough growth hormone naturally. Researchers will measure how safe it is, how your body processes it, and whether it helps you feel better and function more normally.
This study follows adults who had growth hormone deficiency as children and are now part of a research registry. It aims to understand their health outcomes as they transition into adulthood.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
This study looks at how well and how safely Skytrofa (lonapegsomatropin) works for real-world patients in the U.S. It mainly gathers information from routine care to help doctors understand expected benefits and side effects.
This trial is looking at how well Sogroya® (a growth hormone medicine) works when used for a long time in children with short stature caused by growth hormone deficiency. The goal is to see if it helps them grow taller safely.
Hear when a new Adult Growth Hormone Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.